Nuvation Bio Inc. (NUVB)
NYSE: NUVB · Real-Time Price · USD
2.580
-0.010 (-0.39%)
At close: Nov 20, 2024, 4:00 PM
2.500
-0.080 (-3.10%)
After-hours: Nov 20, 2024, 7:34 PM EST
Nuvation Bio Employees
Nuvation Bio had 51 employees as of December 31, 2023. The number of employees decreased by 2 or -3.77% compared to the previous year.
Employees
51
Change (1Y)
-2
Growth (1Y)
-3.77%
Revenue / Employee
$42,392
Profits / Employee
-$10,436,882
Market Cap
868.34M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 51 | -2 | -3.77% |
| Dec 31, 2022 | 53 | -11 | -17.19% |
| Dec 31, 2021 | 64 | 28 | 77.78% |
| Dec 31, 2020 | 36 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Healthcare Services Group | 33,400 |
| Paragon 28 | 574 |
| Immatics | 535 |
| Liquidia | 145 |
| Capricor Therapeutics | 102 |
| 89bio | 70 |
| Tyra Biosciences | 49 |
| ArriVent BioPharma | 40 |
NUVB News
- 8 days ago - Nuvation Bio to Present at the Jefferies London Healthcare Conference - Business Wire
- 10 days ago - Top 4 Health Care Stocks That May Plunge This Quarter - Benzinga
- 14 days ago - Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business Update - Business Wire
- 6 weeks ago - Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer - Business Wire
- 2 months ago - Positive Pooled Data from Nuvation Bio's TRUST-I and TRUST-II Studies Highlight Taletrectinib's Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024 - Business Wire
- 2 months ago - Nuvation Bio to Present at the Cantor Global Healthcare Conference - Business Wire
- 3 months ago - Nuvation Bio: Continuing To Justify A Buy Thesis With Catalysts In 2024 - Seeking Alpha
- 3 months ago - Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update - Business Wire